BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

JNCCN: Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation

New research in the June 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network raises issues with clinical tri...

June 22, 2022 | News

DTx Leader Sidekick Enters Strategic Collaboration with Lilly to Support Patients with Breast Cancer

International digital therapeutics (DTx) innovator, Sidekick Health (www.sidekickhealth.com), today announces an integrated digital therape...

June 20, 2022 | News

Emmes Supports Groundbreaking Anal Cancer Study Sponsored by the National Cancer Institute

Emmes, a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovatio...

June 17, 2022 | News

Nonagen Bioscience announces CE mark for Oncuria® bladder cancer diagnostic

Oncuria is the first-of-its-kind multiplex urine test for the quantitative detection of 10 biomarkers in urine that are associated with the presence of...

June 17, 2022 | News

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotech...

June 16, 2022 | News

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative im...

June 07, 2022 | News

Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02

Everest Medicines (HKEX 1952.HK) announces today that its licensing partner, Gilead Sciences, Inc. (Nasdaq: GILD), reported positive results from the prima...

June 06, 2022 | News

Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways

New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology Clinical trials in locally advanced head ...

June 06, 2022 | News

Boosting CAR-T cells with mRNA Vaccines: New Immunotherapy Strategy

One new strategy aiming to empower CAR T cells against solid tumors is the immunotherapy BNT211, which leverages a BioNTech’s mRNA lipoplex vaccine f...

May 30, 2022 | News

New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment

New findings demonstrate the clinical efficacy of AI-powered tissue analysis as a guide in cancer treatment, according to medical AI provider Lunit. The fi...

May 30, 2022 | News

SeekIn Receives CE Mark Approval for SeekInClarity™ Cancer Treatment Response Monitoring Kit

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (ConformitéEuropéenne) Mark approval...

May 26, 2022 | News

New Horizon Health Partners with Prenetics in Hong Kong to Launch ColoClear, a Non-Invasive Stool DNA Test to Detect Colon Cancer

New Horizon Health and Prenetics will jointly promote ColoClear in Hong Kong, Macau and Taiwan, with additional options to expand the p...

May 24, 2022 | News

ABL & ODIMMA therapeutics join forces in personalized cancer immunotherapy

ABL will manufacture the viral component of Odimma's innovative and proprietary immunization platform ODI-2001. The viral component present in ODI-2001 pla...

May 18, 2022 | News

Inmagene Receives FDA IND Clearance for a Third Generation BTK Inhibitor Targeting Immunological Diseases

The planned Phase 1 study is a double-blind, randomized, placebo-controlled, single and multiple dose escalation study in healthy subjects. The study aims ...

May 16, 2022 | News

Stay Connected